- AbbVie Inc., maker of top-selling drug Humira, had already projected a 9 percent adjusted rate for this year, and posted a minuscule 0.5 percent levy last quarter. The drugmaker says it plans to spend more on research and development and capital projects.
“We view the passage of U.S. tax reform as an important business driver for companies like ours,” AbbVie Chief Executive Officer Richard Gonzalez said last week in a conference call. “Tax reform is having the intended impact.”
This article was provided by Bloomberg News.